Hyung Nam, Ph.D.

Assistant Professor
Ph.D., 2006, Yonsei University
Department of Pharmacology, Toxicology and Neuroscience
1501 Kings Highway
LSU Health Sciences Center
Shreveport, LA 71130-3932
Phone: 318.675.3241
Fax: 318.675.7851
Email: hnam@lsuhsc.edu 

Major Research Interest:
The main goal of our research is to investigate molecular/cellular signaling in alcoholism and psychiatric disorders by using the systems biology approach. The focus of our research is to elucidate the adenosine-glutamate signaling mechanism that underlines relevant alcohol related disorders in rodent models using a combination of cutting-edge techniques in the areas of optogenetics, proteomics, neuropharmacology, and behavioral neuroscience. We believe that linking addictive behaviors with a neuromodulation process by adenosine signaling and also intracellular mechanisms are essential to understanding psychiatric symptoms and how to better treat them.

Ongoing cardiovascular-related projects:

1. Adenosine signaling in alcoholism and cardiovascular disease
Brief description: We have investigated adenosine-glutamate dysregulation induced by excessive alcohol exposure using an adenosine 2A receptor (A2AR) knock out mouse model. Interestingly, adenosine 2A receptor also plays an essential role in neuro-protective effect of ischemia in the neuronal and cardiovascular systems. We have tested the comorbidity between an alcohol use disorder and neurovascular disease using KO mouse model and adenosine pharmacology. In addition, since excessive ethanol drinking also induces cardiomyopathy and arrhythmias that is possibly regulated by adenosine signaling, we will explore the effect of adenosine pharmacology in the cardiovascular system.
Names of collaborators / collaborating institutions: none
Funding source: none

2. Pharmacometabolomics for bipolar disorders with cardiovascular disease.
Brief description: We have studied drug efficacy biomarkers using a metabolomics platform to elucidate pharmacological intervention in psychiatric disorders including alcoholism and bipolar disorders. Many anti-psychotic medications induce the cardiovascular related side effect or worsen the patients who already has cardiovascular failure for inevitable accompaniments to heart disease. Therefore, we are spearheading a biomarker project using the blood specimens from bipolar disorder patients with/without comorbid cardiovascular disease.
Names of collaborators / collaborating institutions: Mark Frye MD, Richard Weinshilboum MD/ Mayo Clinic
Funding source: NARSAD Young Investigator Award

Methods and Available Resources:

  1. Proteomics and metabolomics using mass spectrometry
  2. Animal behavior tests
  3. Optogenetics and in vivo bran micro-dialysis
  4. Viral mediated gene expression in brain tissue

Publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=hyung+wook+nam